Table 1.

Clinical characteristics of 14 HLA-B*57 participants from the MACS cohort

Participant	HLA genotype						Characteristics at time of sampling			Long-term outcome
							Time (mo) since infectiona	CD4b	VLc	Event	Time (yr) to eventd
A	A0100	A3000	B1801	B5701	C0501	C0602	0–12	833	20,501	Death	3.5
B	A0201	A3301	B3501	B5701	C0401	C0602	5–6	789	14,811	Death	5.5
C	A0101	A0201	B4402	B5701	C0501	C0602	0–24	317	30,468	CD4 < 200	6
D	A0101	A2402	B4401	B5701	C0304	C0602	0–6	1098	8,868	CD4 < 200	6
E	A0201	A0201	B5001	B5701	C0602	C0602	10–15	800	2,927	CD4 < 200	6.25
F	A0101	A0201	B0702	B5701	C0602	C0702	0–6	744	11,955	CD4 < 200	9
G	A0101	A0201	B5701	B5701	C0602	C0702	0–7	665	4,414	CD4 < 200	11
H	A0101	A2501	B1801	B5701	C0602	C1203	0–6	1637	3,151	CD4 < 200	12
I	A0201	A0201	B1501	B5701	C0304	C0602	3–8	958	4,989	cART	13
J	A0100	A2400	B4403	B5701	C0303	C0602	4–6	801	43,400	Nonee	13
K	A0101	A0201	B5101	B5701	C0602	C0702	0–6	757	109,373	CD4 < 200	13.5
L	A0200	A3201	B0702	B5701	C0602	C0700	9–15	853	82,009	CD4 < 200	15
M	A0201	A6801	B5703	B5802	C0602	C1801	6–12	642	5,538	cART	17
N	A0101	A0301	B1518	B5701	C0602	C0704	0–9	1200	< 400	Nonee	25

^aNumber of months that elapsed between seroconversion and donation of the samples used in this study.

^bNumber of CD4⁺ T lymphocytes/mm³ of blood at the time of sampling.

^cNumber of HIV-1 RNA copies/ml of plasma at the time of sampling.

^dNumber of years elapsed between date of infection and the earliest of the following events: decline of CD4⁺ T cell counts below 200/mm³, initiation of combination antiretroviral therapy (cART), or death.

^eParticipants J and N still had CD4 counts above 200, as of 2011.